Targeted Genetics, a Seattle-based developer of gene therapies, said today that it only has enough cash to run its operations into the first quarter of 2009. Targeted (NASDAQ: [[ticker:TGEN]]) said it had $9.2 million in cash and investments left at the end of September, and that it estimates it will spend $11.5 million to $12.5 million throughout 2008. The company is now collaborating with the University of Iowa on an experimental treatment for ALS, or Lou Gehrig’s disease.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
